istari oncology series a | Istari Oncology

Keyword	CPC	PCC	Volume	Score	Length of keyword
istari oncology series a	1.85	0.9	8881	6	24
istari	0.05	0.6	1584	88	6
oncology	0.48	0.1	3942	9	8
series	1.33	0.3	6223	73	6
a	0.06	0.8	1019	19	1

Keyword	CPC	PCC	Volume	Score
istari oncology series a	0.04	0.9	1319	91

Search Results related to istari oncology series a on Search Engine

Istari Oncology
istarioncology.com

https://www.istarioncology.com/

WEBOctober 18, 2022. Istari Oncology Announces Presentation of Clinical Responses from LUMINOS-102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory …

DA: 33 PA: 41 MOZ Rank: 61

Istari Oncology Announces FDA Granted Fast Track Designation …
istarioncology.com

https://www.istarioncology.com/news-post/istari-oncology-announces-fda-granted-fast-track-designation-to-pvsripo-for-the-treatment-of-advanced-melanoma

WEBDURHAM, NC – June 14, 2021 - Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors, …

DA: 52 PA: 66 MOZ Rank: 49

Istari Oncology Initiates Its Phase I/II Sub-Study …
businesswire.com

https://www.businesswire.com/news/home/20210817005503/en/Istari-Oncology-Initiates-Its-Phase-III-Sub-Study-Evaluating-PVSRIPO-in-Patients-with-Head-and-Neck-Cancer

WEBAug 17, 2021 · DURHAM, N.C.-- ( BUSINESS WIRE )-- Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the …

DA: 81 PA: 42 MOZ Rank: 39

Istari Oncology Announces Publication of Phase 1 Data …
businesswire.com

https://www.businesswire.com/news/home/20210421005855/en/Istari-Oncology-Announces-Publication-of-Phase-1-Data-Showing-PVSRIPO-Immunotherapy-Leads-to-Objective-Responses-in-Patients-with-Treatment-Refractory-Melanoma

WEBApril 21, 2021 12:34 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Istari Oncology, Inc., a clinical-stage biotechnology company, today announced the …

DA: 21 PA: 61 MOZ Rank: 88

Istari Oncology Announces FDA Granted Fast Track …
businesswire.com

https://www.businesswire.com/news/home/20210614005220/en/Istari-Oncology-Announces-FDA-Granted-Fast-Track-Designation-to-PVSRIPO-for-the-Treatment-of-Advanced-Melanoma

WEBJun 14, 2021 · DURHAM, N.C.-- ( BUSINESS WIRE )-- Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors, announced …

DA: 39 PA: 81 MOZ Rank: 43

Istari Oncology Announces FDA Grants Orphan Drug …
duke.edu

https://otc.duke.edu/news/istari-oncology-announces-fda-grants-orphan-drug-designation-for-pvsripo/

WEBDURHAM, NC, January 10, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has …

DA: 68 PA: 14 MOZ Rank: 87

Startup Spotlight: Istari Oncology enters agreement with …
wraltechwire.com

https://wraltechwire.com/2021/11/01/startup-spotlight-istari-oncology-fujifilm-diosynth-biotechnologies-deal/

WEBNov 1, 2021 · Six months after a massive $43.4 million raise, Istari Oncology, a clinical-stage biotech company headquartered in Durham, has entered into an agreement with …

DA: 58 PA: 38 MOZ Rank: 93

Istari Oncology, now with FDA clearance for PVSRIPO, raises …
wraltechwire.com

https://wraltechwire.com/2021/04/22/fda-clears-durham-based-istari-oncology-investigational-new-drug-application/

WEBApr 22, 2021 · Following the filing, the Durham-based clinical-stage biotechnology company received clearance from the U.S. Food and Drug Administration (FDA) for its …

DA: 44 PA: 2 MOZ Rank: 76

Flush With Cash, Istari Expands Revolutionary …
ncbiotech.org

https://www.ncbiotech.org/news/flush-cash-istari-expands-revolutionary-treatment-trial-using-polio-vaccine

WEBAug 19, 2021 · Months after a massive $43.4 million raise, Istari Oncology, a clinical-stage biotech company headquartered in Durham, has expanded its LUMINOS-103 trial. It …

DA: 30 PA: 64 MOZ Rank: 47